From PsychonautWiki
Jump to navigation Jump to search

Template:SubstanceBox/EiPLA N-Ethyl-N-isopropyllysergamide (also known as Ethylisopropyllysergamide and EiPLA) is a lesser-known novel psychedelic substance of the lysergamide class. EiPLA is structurally related to LSD and MiPLA and likely has a similar mechanism of action, working primarily by binding to the serotonin-2A receptor in the brain.[citation needed]


The chemical name of EiPLA is Ethylisopropyllysergamide. EiPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is LSD, lysergic acid diethylamide.

EiPLA is a structural isomer of LSD. Like LSD, the chemical structure of EiPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, EiPLA is substituted with a ethyl and isopropyl group.

EiPLA is a chiral compound with two stereocenters at R5 and R8.


As with its structurally related lysergamides, EiPLA principally acts as a 5-HT2A partial agonist, through which it exerts its psychedelic effects. However, the role of these interactions and how they result in the psychedelic experience is unclear.

Owing to similarities in chemical structure, EiPLA and LSD have highly similar binding profiles at monoamine receptors (i.e. serotonin, dopamine, and norepinephrine).[citation needed]

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

EiPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Transpersonal effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational MiPLA use has not been studied in any scientific context and the exact toxic dose is unknown. This is because MiPLA is a research chemical with very little history of human usage.

The current body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

However, as is the case for LSD, it is possible that MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.


The LD50 of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include anxiety, delusions, panic attacks and (more rarely) seizures. Medical attention is usually only needed in the case of severe psychotic episodes or “fake acid” (a counterfeit substance such as 25x-NBOMe or DOx). Administration of benzodiazepines or antipsychotics can help to relieve the negative psychological effects of MiPLA.

Dependence and abuse potential

Like other serotonergic psychedelics, MiPLA is believed to have a low potential for abuse and dependence. This is owing to its structural and pharmacological similarities with LSD. See this section to learn more about the dependence and abuse potential of LSD. It should be noted that all claims related to the abuse potential of MiPLA are preliminary and based on anecdotal (as opposed to clinical) evidence and should be interpreted with caution.

As with LSD, tolerance to the effects of MiPLA forms almost immediately after ingestion. After that, it is assumed to take about 5-7 days for the tolerance to be reduced to half and 14 days to be return to baseline (in the absence of further consumption).

Due to its activity at the 5-HT2A receptor, MiPLA produces cross-tolerance with all psychedelics, meaning that after the consumption of MiPLA all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

MiPLA is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area throughout most of the world, meaning that it might not be specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

  • Austria: MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. [citation needed]
  • Germany: MiPLA is controlled under the NpSG (New Psychoactive Substances Act)[2] as of July 18, 2019.[3] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[4]
  • United States: MiPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.[citation needed]

See also

External links




  1. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  2. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  3. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020. 
  4. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.